Status:
COMPLETED
Depression in Alzheimer's Disease-2
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Alzheimer's Disease
Depression
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's...
Detailed Description
Participants are randomly assigned to treatment with sertraline (range 25-125 mg per day) or identical placebo for 24 weeks. There are 8 scheduled in-person visits in the 24 weeks. Visits include neur...
Eligibility Criteria
Inclusion
- Inclusion:
- Ability of the participant, caregiver or surrogate to provide written informed consent.
- Dementia due to Alzheimer's disease
- Stable treatment for Alzheimer's disease
- Ability for the participant's caregiver to accompany the participant to study visits and participate in the study.
- Exclusion
- Presence of a brain disease that might otherwise explain the presence of dementia
- Clinically significant hallucinations or delusions
- Current treatment of antipsychotics, anticonvulsants, and other antidepressants, benzodiazepines, or other psychotropic medications
- Need for hospitalization or residence in a nursing facility
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT00086138
Start Date
July 1 2004
End Date
July 1 2009
Last Update
April 11 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California
Los Angeles, California, United States, 90033
2
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
3
University of Rochester
Rochester, New York, United States, 14620
4
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104